



Monitoring TAG's Recommendation to Lower the Age of MMR2 to 18 Months Between 2014 and 2019

Countries who administered the second dose of measles-mumps-rubella vaccine (MMR2) between 4-7 years old are encouraged to conduct a follow-up campaign **before lowering** the age, to guarantee that children aged between 2 and 7 years received two doses of this vaccine.

Lower the age (18 months)	Not lower the age (4-7 years)	Introduced MMR2 at 18 months
Antigua & Barbuda	Argentina	Bolivia
Belize	Chile	Dominica
Bahamas	Canada	Guatemala
Barbados	Colombia	Haiti ^(b)
Brazil ^(a)	Costa Rica	Honduras
Ecuador	Cuba	Nicaragua
Guyana	Mexico	Dominican Republic
Jamaica	Paraguay	
Panama	El Salvador	
Peru	United States	
St. Kitts & Nevis		
St. Vincent & Grenadines		
Saint Lucia		
Suriname		
Trinidad and Tobago		
Venezuela		

^(a) at 15 months
^(b) at 13 months. The country uses the measles-rubella (MR) vaccine.

Sources: PAHO-WHO/UNICEF Joint Reporting Form (JRF) on immunization, 2020 (2019 data).

Table.1
Classification of Suspect Measles, Rubella, and Congenital Rubella Syndrome (CRS) Cases for Weeks 01-40, 2020

Subregion and Country	Susp. Cases 2020	Measles Confirmed 2020				Year/Week Last Conf. Measles case	Rubella Confirmed 2020			Year/Week Last Conf. Rubella Case	Diagnosis of Discarded Cases 2020		Congenital Rubella Syndrome			Year/Week Last Conf. CRS Case	
		Clin.	Lab.	EPI link	Total		Clin.	Lab.	Total		Dengue	Others	Susp.	Conf.	CRIs*		
AND	BOL	60	0	2	...	2	2020-16	0	0	0	2006-03	16	41	0	0	0	...
	COL	594	...	1	...	1	2020-09	0	0	0	2012-31	0	472	156	0	0	2005-34
	ECU	2018-33	2004-49	2011-14
	PER	58	0	0	...	0	2019-18	0	0	0	2009-04	0	54	0	0	0	2007-16
	VEN	515	0	0	...	0	2019-33	0	0	0	2007-51	32	352	0	0	0	...
BRA	BRA	16580	2801	5386	...	8187	2020-39	0	0	0	2014-40	0	7860	30	0	0	2009-34
	CAP	68	0	0	...	0	2019-13	0	0	0	2001-39	4	36	81	0	0	...
	GTM	51	0	0	...	0	2018-03	0	0	0	2006-31	1	49	1	0	0	2005-00
	HND	83	0	0	...	0	1998-16	0	0	0	2004-11	0	82	7	0	0	2001-00
	NIC	87	0	0	...	0	1994-14	0	0	0	2004-19	5	73	21	0	0	2005-00
	PAN	28	0	0	...	0	2011-20	0	0	0	2002-48	0	27	0	0	0	...
	SLV	138	0	0	...	0	2001-19	0	0	0	2006-30	0	138	181	0	0	2001-00
CAR	CAR	50	0	0	...	0	2019-48	0	0	0	2008-18	0	48	12	0	0	1999-00
	LAC	906	0	0	...	0	2019-24	0	0	0	2004-06	0	906	0	0	0	1989-10
	DOM	15	0	0	...	0	2011-18	0	0	0	2007-45	4	8	0	0	0	...
	HTI	108	0	0	...	0	2001-39	0	0	0	2006-21	0	73	32	0	0	...
MEX	MEX	2211	...	185	10	195	2020-23	0	0	0	2018-14	0	1929	0	0	0	...
	NOA	1	...	1	2020-06	0	0	0	2019-50	2018-39
	USA	12	...	12	2020-10	2019-03	2017-00
SOC	ARG	326	0	60	1	61	2020-12	0	0	0	2019-47	3	261	0	0	0	2009-27
	CHL	38	0	2	...	2	2020-03	0	0	0	2019-14	0	32	0	0	0	...
	PRY	506	0	0	...	0	1998-44	0	0	0	2005-21	2	436	6	0	0	2003-06
	URY	9	0	0	2	2	2020-07	0	0	0	2001-37	0	6	0	0	0	...
TOTAL	22431	2801	5649	13	8463	--	0	0	0	--	67	12883	527	0	0	0	--

*Congenital Rubella Infection.

...No updated report received



Measles, Rubella, and Congenital Rubella Syndrome Surveillance in the Americas

Vol. 26, No. 40

Table No.2
Infection Source of Measles and Rubella Confirmed Cases
for the Period of Weeks 01-40, 2020

Subregion and Country		Measles				Rubella		
		I	IR	En.	U	I	IR	U
AND	BOL				2			
	COL	1						
	ECU							
	PER							
	VEN							
BRA CAP	BRA			8187				
	CRI							
	GTM							
	HND							
	NIC							
CAR LAC	PAN							
	SLV							
	CAR							
	CUB							
	DOM							
MEX NOA	HTI							
	MEX*							
SOC	CAN	1						
	USA	12						
	ARG	7			54			
	CHL	2						
	URY		2					
TOTAL		23	2	8187	56	0	0	0

I: Imported; IR: Import-related; En: Endemic case; U: Unknown.
* Pending final classification

Table No.3
Measles/Rubella Suspect Cases Under Investigation
for the Period of Weeks 01-40, 2020

Country	Pending Cases 2019	Cumulative 2020	Week of Onset							% Pend. Cases
			1-35	36	37	38	39	40		
BOL	1	1	1	0	0	0	0	0	0	2
COL	122	121	102	3	8	6	2	0	0	20
ECU	8
PER	13	4	4	0	0	0	0	0	0	7
VEN	6	1	1	0	0	0	0	0	0	0
BRA	2597	533	438	7	19	19	22	21	3	3
CRI	0	28	28	0	0	0	0	0	41	41
GTM	0	1	1	0	0	0	0	...	2	2
HND	0	1	1	0	0	0	0	0	1	1
NIC	0	9	3	1	2	0	1	2	10	10
PAN	1	1	1	0	0	0	0	0	4	4
SLV	0	0	0	0	0	0	0	...	0	0
CAR	6	2	1	0	0	1	0	0	4	4
CUB	0	0	0	0	0	0	0	0
DOM	20	3	3	20	20
HTI	29	35	33	0	2	0	0	0	32	32
MEX	248	86	55	2	3	7	11	8	4	4
CAN
USA
ARG	5	1	1	0	0	0	0	0	0	0
CHL	9	4	4	11	11
PRY	85	65	57	1	0	3	1	3	12	12
URY	3	1	1	0	11	11
TOTAL	3153	897	735	14	34	36	37	34	4	4

... No updated report received

Table 4
Indicators of Integrated Measles/Rubella Surveillance for Period of Weeks 01-40, 2020

Subregion and Country		Sites Reporting Weekly		% Cases with Adequate Investigation	% Cases with Adequate Sample	% Blood Samples Received in Lab. ≤5 days	% Lab. Results ≤4 days	Rate of Suspected Cases Last 52 weeks (2019/41-2020/40)	
		Total Units	% This Week					Measles/Rubella (100,000 pop.)	CRS (10,000 lb)
AND	BOL	2657	...	87	92	68	85	0.8	0.0
	COL	4612	...	54	2.4	7.1
	ECU	2184
	PER	7781	...	91	83	70	58	0.4	0.0
	VEN	13092	...	100	96	13	12	0.7	0.3
CAP	BRA	70	55	16.2	0.1
	CRI	57	144	94	59	98	95	1.5	20.3
	GTM	1541	...	98	100	61	86	0.4	0.0
	HND	469	92	96	100	81	100	1.8	1.7
	NIC	185	100	95	98	95	98	2.0	4.3
CAR LAC	PAN	324	...	93	96	71	89	0.9	0.0
	SLV	1288	...	87	99	97	93	3.3	0.0
	CAR	763	66	60	94	22	73	1.4	1.0
	LAC	168	...	100	100	100	100	11.9	0.0
	DOM	247	...	53	93	80	53	0.2	0.0
MEX NOA	HTI	659	93	90	96	56	50	1.1	2.3
	MEX	20099	96	96	99	94	89	2.2	0.0
SOC	CAN
	USA
	ARG	784	...	7	92	67	52	1.9	0.0
	CHL	767	...	8	95	92	94	0.7	7.4
	PRY	1291	98	74	91	83	92	12.7	0.9
URY	155	...	67	33	38	38	0.3	0.0	
Total and Average*		59123	38	84	97	73	61	7.3	0.9

*Weighted

... No updated report received